Does the media refer more to RYTM or ZYME?

In the previous week, Zymeworks had 23 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 38 mentions for Zymeworks and 15 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.44 beat Zymeworks' score of 0.86 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 14 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZYME or ORKA?

In the previous week, Zymeworks had 26 more articles in the media than Oruka Therapeutics. MarketBeat recorded 38 mentions for Zymeworks and 12 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat Zymeworks' score of 0.86 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 14 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, ZYME or CGON?

Zymeworks has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zymeworks $37.13M 54.03 -$81.13M -$2.02 N/A CG Oncology $6.23M 1,058.04 -$160.99M -$2.69 N/A

Is ZYME or CGON more profitable?

Zymeworks has a net margin of -405.31% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Zymeworks -405.31% -72.30% -37.18% CG Oncology -3,602.68% -25.20% -23.98%

Does the media favor ZYME or CGON?

In the previous week, Zymeworks had 32 more articles in the media than CG Oncology. MarketBeat recorded 38 mentions for Zymeworks and 6 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.37 beat Zymeworks' score of 0.86 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 14 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZYME or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Zymeworks -405.31% -72.30% -37.18% Scholar Rock N/A -160.19% -87.18%

Does the media prefer ZYME or SRRK?

In the previous week, Zymeworks had 28 more articles in the media than Scholar Rock. MarketBeat recorded 38 mentions for Zymeworks and 10 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.49 beat Zymeworks' score of 0.86 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 14 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZYME or MIRM?

In the previous week, Zymeworks had 18 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 38 mentions for Zymeworks and 20 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.27 beat Zymeworks' score of 0.86 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 14 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zymeworks (ZYME) Competitors

$28.27 -0.74 (-2.55%)

As of 08/28/2026 04:00 PM Eastern

Compare

ZYME vs. RYTM, ORKA, CGON, SRRK, and MIRM

Should you buy Zymeworks stock or one of its competitors? Zymeworks's main competitors and comparable companies include Rhythm Pharmaceuticals (RYTM), Oruka Therapeutics (ORKA), CG Oncology (CGON), Scholar Rock (SRRK), and Mirum Pharmaceuticals (MIRM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zymeworks compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Zymeworks (NASDAQ:ZYME) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Zymeworks has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	30.61	-$196.54M	-$3.11	N/A
Zymeworks	$37.13M	54.03	-$81.13M	-$2.02	N/A

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Zymeworks	-405.31%	-72.30%	-37.18%

In the previous week, Zymeworks had 23 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 38 mentions for Zymeworks and 15 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.44 beat Zymeworks' score of 0.86 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	14 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Zymeworks shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 33.5% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rhythm Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Rhythm Pharmaceuticals presently has a consensus target price of $141.12, indicating a potential upside of 31.68%. Zymeworks has a consensus target price of $40.00, indicating a potential upside of 41.49%. Given Zymeworks' higher probable upside, analysts plainly believe Zymeworks is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Zymeworks beats Rhythm Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Oruka Therapeutics?

Zymeworks (NASDAQ:ZYME) and Oruka Therapeutics (NASDAQ:ORKA) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Zymeworks currently has a consensus price target of $40.00, suggesting a potential upside of 41.49%. Oruka Therapeutics has a consensus price target of $134.30, suggesting a potential upside of 47.36%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Oruka Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Oruka Therapeutics' return on equity of -21.65% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Oruka Therapeutics	N/A	-21.65%	-20.88%

In the previous week, Zymeworks had 26 more articles in the media than Oruka Therapeutics. MarketBeat recorded 38 mentions for Zymeworks and 12 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat Zymeworks' score of 0.86 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	14 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zymeworks has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$37.13M	54.03	-$81.13M	-$2.02	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Zymeworks has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its stock price is 134% less volatile than the broader market.

Summary

Zymeworks beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Zymeworks compare to CG Oncology?

Zymeworks (NASDAQ:ZYME) and CG Oncology (NASDAQ:CGON) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, Zymeworks had 32 more articles in the media than CG Oncology. MarketBeat recorded 38 mentions for Zymeworks and 6 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.37 beat Zymeworks' score of 0.86 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	14 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zymeworks has a net margin of -405.31% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
CG Oncology	-3,602.68%	-25.20%	-23.98%

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zymeworks has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

Zymeworks presently has a consensus price target of $40.00, indicating a potential upside of 41.49%. CG Oncology has a consensus price target of $83.18, indicating a potential upside of 11.89%. Given Zymeworks' stronger consensus rating and higher probable upside, equities research analysts plainly believe Zymeworks is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Zymeworks has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$37.13M	54.03	-$81.13M	-$2.02	N/A
CG Oncology	$6.23M	1,058.04	-$160.99M	-$2.69	N/A

Summary

Zymeworks beats CG Oncology on 11 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Scholar Rock?

Zymeworks (NASDAQ:ZYME) and Scholar Rock (NASDAQ:SRRK) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Comparatively, 10.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Zymeworks had 28 more articles in the media than Scholar Rock. MarketBeat recorded 38 mentions for Zymeworks and 10 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.49 beat Zymeworks' score of 0.86 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	14 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Scholar Rock	N/A	-160.19%	-87.18%

Zymeworks has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Zymeworks has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$37.13M	54.03	-$81.13M	-$2.02	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Zymeworks currently has a consensus target price of $40.00, indicating a potential upside of 41.49%. Scholar Rock has a consensus target price of $58.77, indicating a potential upside of 1.68%. Given Zymeworks' higher probable upside, equities research analysts plainly believe Zymeworks is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13

Summary

Zymeworks beats Scholar Rock on 11 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Mirum Pharmaceuticals?

Zymeworks (NASDAQ:ZYME) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

92.9% of Zymeworks shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Mirum Pharmaceuticals has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$37.13M	54.03	-$81.13M	-$2.02	N/A
Mirum Pharmaceuticals	$618.07M	10.24	-$23.36M	-$14.55	N/A

In the previous week, Zymeworks had 18 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 38 mentions for Zymeworks and 20 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.27 beat Zymeworks' score of 0.86 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	14 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zymeworks has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Mirum Pharmaceuticals has a net margin of -139.18% compared to Zymeworks' net margin of -405.31%. Mirum Pharmaceuticals' return on equity of -36.28% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Zymeworks presently has a consensus target price of $40.00, indicating a potential upside of 41.49%. Mirum Pharmaceuticals has a consensus target price of $137.31, indicating a potential upside of 40.89%. Given Zymeworks' higher possible upside, analysts plainly believe Zymeworks is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Mirum Pharmaceuticals beats Zymeworks on 10 of the 17 factors compared between the two stocks.

Get Zymeworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYME vs. The Competition

Export

Metric	Zymeworks	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.01B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-14.00	11.62	273.16	25.45
Price / Sales	54.03	1,295.89	605.01	76.63
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	25.02	16.53	12.98	6.14
Net Income	-$81.13M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-1.40%	-0.31%	0.13%	-0.80%
1 Month Performance	24.48%	9.80%	7.08%	4.13%
1 Year Performance	90.88%	55.66%	24.67%	15.17%

Zymeworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYME Zymeworks	2.8384 of 5 stars	$28.27 -2.6%	$40.00 +41.5%	+90.9%	$2.01B	$37.13M	N/A	460	Trending News Analyst Forecast Analyst Revision
RYTM Rhythm Pharmaceuticals	2.8741 of 5 stars	$110.00 +1.0%	$142.44 +29.5%	+3.9%	$7.46B	$189.76M	N/A	140	Positive News Analyst Forecast Gap Down
ORKA Oruka Therapeutics	2.8907 of 5 stars	$107.96 +3.0%	$134.30 +24.4%	+515.8%	$6.94B	N/A	N/A	N/A	News Coverage Positive News
CGON CG Oncology	3.242 of 5 stars	$79.81 +2.8%	$83.18 +4.2%	+177.2%	$6.88B	$4.04M	N/A	61
SRRK Scholar Rock	1.768 of 5 stars	$56.50 +2.3%	$58.77 +4.0%	+77.0%	$6.73B	N/A	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYME) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zymeworks (ZYME) Competitors

ZYME vs. RYTM, ORKA, CGON, SRRK, and MIRM

How does Zymeworks compare to Rhythm Pharmaceuticals?

Summary

How does Zymeworks compare to Oruka Therapeutics?

Summary

How does Zymeworks compare to CG Oncology?

Summary

How does Zymeworks compare to Scholar Rock?

Summary

How does Zymeworks compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zymeworks (ZYME) Competitors

ZYME vs. RYTM, ORKA, CGON, SRRK, and MIRM

How does Zymeworks compare to Rhythm Pharmaceuticals?

Which has higher earnings and valuation, RYTM or ZYME?

Is RYTM or ZYME more profitable?

Does the media refer more to RYTM or ZYME?

Do insiders & institutionals have more ownership in RYTM or ZYME?

Which has more volatility and risk, RYTM or ZYME?

Do analysts recommend RYTM or ZYME?

Summary

How does Zymeworks compare to Oruka Therapeutics?

Do analysts prefer ZYME or ORKA?

Is ZYME or ORKA more profitable?

Does the media favor ZYME or ORKA?

Which has preferable earnings and valuation, ZYME or ORKA?

Do institutionals and insiders hold more shares of ZYME or ORKA?

Which has more risk and volatility, ZYME or ORKA?

Summary

How does Zymeworks compare to CG Oncology?

Does the media favor ZYME or CGON?

Is ZYME or CGON more profitable?

Do insiders and institutionals believe in ZYME or CGON?

Which has more risk and volatility, ZYME or CGON?

Do analysts rate ZYME or CGON?

Which has preferable earnings and valuation, ZYME or CGON?

Summary

How does Zymeworks compare to Scholar Rock?

Do insiders and institutionals have more ownership in ZYME or SRRK?

Does the media prefer ZYME or SRRK?

Is ZYME or SRRK more profitable?

Which has more risk and volatility, ZYME or SRRK?

Which has stronger earnings and valuation, ZYME or SRRK?

Do analysts rate ZYME or SRRK?

Summary

How does Zymeworks compare to Mirum Pharmaceuticals?

Do insiders & institutionals believe in ZYME or MIRM?

Which has preferable earnings & valuation, ZYME or MIRM?

Does the media favor ZYME or MIRM?

Which has more risk and volatility, ZYME or MIRM?

Is ZYME or MIRM more profitable?

Do analysts prefer ZYME or MIRM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools